Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Portal Biotechnologies
AddedJun 25, 2026
UpdatedJun 25, 2026
Portal Biotechnologies

Portal Biotechnologies

Series A

Portal Biotechnologies is a Watertown, Massachusetts-based cell engineering and drug discovery platform company founded in 2023.

HQ
Watertown, MA, US
Founded
2023
Overview
Analysis
Compare
Fundraising
Employees
News

Portal Biotechnologies develops a universal cell engineering platform built on proprietary mechanical membrane-disruption technology. Its system enables high-throughput, scalable intracellular delivery of RNA, gene editors, probes, and other cargos into diverse hard-to-transfect cell types for research and therapeutic applications.

The company supports drug discovery workflows, AI data generation, and cell therapy partnerships, and has reported more than 100 customers across top pharmaceutical and academic centers. It was established in 2023 and is led by founder and CEO Armon Sharei, Ph.D.

Portal Biotechnologies - Products & Services

  • Gateway System logo

    Gateway System

    Gateway System is Portal's research-scale mechanical delivery instrument for intracellular cargo.

    Competing Products

    Bio-Rad logo
    Thermo Fisher th logo

Portal Biotechnologies - Similar Companies

Bio-Rad logo

Bio-Rad

bio-rad.com

Thermo Fisher th logo

Thermo Fisher th

thermofisher.com

Portal Instruments logo

Portal Instruments

Mana.bio logo

Mana.bio

mana.bio

Sigma Genetics logo

Sigma Genetics

sigmagenetics.com

Rogo logo

Rogo

rogo.ai

CellFE logo

CellFE

Gate Bioscience logo

Gate Bioscience

gatebio.com

Mekonos logo

Mekonos

mekonos.com

Optimeos Life Sciences logo

Optimeos Life Sciences

optimeos.com

Kytopen logo

Kytopen

kytopen.com

Entrada Therapeutics logo

Entrada Therapeutics

entradatx.com

Gatehouse Bio logo

Gatehouse Bio

gatehousebio.com

ParcelBio logo

ParcelBio

parcelbio.com

Nanotransfer logo

Nanotransfer

nanotransfer.bio

Portal Biotechnologies - Quick Facts

Who are Portal Biotechnologies' competitors?

Companies similar to Portal Biotechnologies include Bio-Rad, Thermo Fisher th, Portal Instruments and Mana.bio.

When was Portal Biotechnologies founded?

Portal Biotechnologies was founded in 2023.

Where is Portal Biotechnologies' headquarters located?

Portal Biotechnologies' headquarters is located in Watertown, MA, US.

When was Portal Biotechnologies' last funding round?

Portal Biotechnologies' most recent funding round was for $9M (USD) in June 2026.

How much has Portal Biotechnologies raised to-date?

As of Jun 19, 2026, Portal Biotechnologies has raised a total of $9M (USD).

Portal Biotechnologies - Classification

Industry
  • Biotechnology
Model
  • Platform
Revenue
  • B2B
Customer
  • Enterprise